Wegovy's UK Approval History — and What It Means Right Now

The common misconception: one approval date, one product

Ask ten people when Wegovy was approved in the UK and most will give you a single year. The reality is a sequence. The MHRA granted the original UK marketing authorisation for the Wegovy 2.4mg weekly injection in 2021, but actual supply and clinical use only became meaningful once shortages eased and NICE issued its funding recommendation in March 2023 under appraisal TA875. So the 2021 date is accurate but incomplete: approval to sell a medicine is not the same as availability on prescriptions.

What followed is the part most people miss. In January 2026 the MHRA approved a higher 7.2mg maintenance dose of Wegovy (initially supplied as three 2.4mg pens per week) for adults with obesity. Trials reported around 20.7% average weight loss at 72 weeks at that dose, narrowing the gap with tirzepatide's results. Then, on 14 April 2026, a dedicated single-dose 7.2mg pen received MHRA approval: one pre-set weekly injection with a built-in covered needle that locks after use. Cleaner, simpler, no calculating. The licensed maximum dose is now 7.2mg, reached by titration from 0.25mg under prescriber supervision. For a fuller look at how the semaglutide approval timeline developed, our semaglutide approval date page traces the earlier milestones in detail.

The misconception to correct first, then, is this: Wegovy is not a single static product. It has grown (in dose options, in delivery format, and in licensed indications) across several distinct regulatory decisions.

June 2026: oral tablets and a different kind of first

On 11 June 2026 the MHRA approved Wegovy tablets, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet contains semaglutide co-formulated with an absorption enhancer. Its dosing ladder runs 1.5mg, 4mg, 9mg, and 25mg, a different set of strengths from the Rybelsus diabetes tablet, which uses 3mg, 7mg and 14mg. The two products are not interchangeable and serve entirely different licensed purposes.

The phase 3 OASIS 4 trial (307 adults, 64 weeks, compared against placebo alongside lifestyle changes) reported around 13.6% average weight loss regardless of adherence. Among participants who stayed fully adherent throughout, that figure rose to around 16.6%. One practical point the tablet changes: no refrigeration. The injection pen lives in the fridge door; the tablet sits in a bathroom cabinet or slips into a handbag without a cold bag. For people who travel frequently or find injections a barrier, that difference matters.

The tablet has no NICE appraisal yet, so it is not available on the NHS. You can read more about the specific approvals on our Wegovy approval for weight loss page, or explore the broader semaglutide overview if you want to understand the molecule behind both Wegovy and Ozempic.

NICE, the NHS, and why approval alone doesn't mean access

MHRA approval permits a medicine to be sold in the UK. It says nothing about who pays. NICE appraisal TA875, published in March 2023, recommended the Wegovy injection for NHS use, but within tight conditions. Treatment is restricted to a maximum of two years, must be delivered within a specialist weight management service with multidisciplinary support, and applies to adults with a BMI of 35 or above and at least one weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. If less than 5% weight is lost after six months on the maintenance dose, continuing treatment is reviewed. The NHS England weight management injections page sets out the wraparound care requirements in full.

In practice, NHS waiting lists for specialist services are long in most areas. Many people whose BMI or health profile would qualify find that the phased rollout hasn't reached their cohort yet, or that their local service isn't accepting referrals. That's where private prescribing fills a genuine gap: a GPhC-registered online pharmacy can complete a clinical assessment and issue a prescription on the same day if you're clinically suitable, without a referral or a queue. Pricing context for private treatment is covered on our Wegovy prices page.

One approval the page would be incomplete without mentioning: on 3 July 2026, the MHRA granted Wegovy a conditional approval to treat MASH, a form of fatty liver disease with moderate-to-advanced fibrosis. This is outside the weight-management indication, and it's explored separately at semaglutide MASH approval.

What the approval sequence means if you're considering Wegovy now

Regulatory history is only useful if it helps you make a decision. Here's what the timeline actually tells you. First, Wegovy has been through multiple rigorous MHRA reviews, not a single approval six years ago but an ongoing regulatory relationship that has added a higher dose, a new delivery device, a tablet formulation and a new therapeutic indication. That depth of scrutiny is a reasonable proxy for confidence in the medicine's safety and efficacy profile.

Second, the product you'd be prescribed today may look different from what your friend started two years ago. Dose options are broader; delivery formats have changed. A prescriber will assess which option suits your circumstances and health history, not simply offer whichever pen has the lowest dose number. Third, the weight outcomes vary by dose: the 2.4mg injection produced around 15% average weight loss in the STEP 1 trial over 68 weeks, while the 7.2mg dose achieved around 20.7%. Whether those figures translate to your situation is genuinely a clinical question, not something a webpage can answer. For more on the long-term picture, whether Wegovy weight loss is permanent is worth reading before you start.

If you'd like a prescriber to assess whether Wegovy is right for you, start your free consultation with our clinical team.